Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

By C. Gabay, P. Emery, Ronald F van Vollenhoven, A. Dikranian, R. Alten, K. Pavelka, M. Klearman, D. Musselman, S. Agarwal, Jennifer Green and 1 more. The Lancet, 2013

672 citations recorded by the source corpus.

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/2495f7d992ddf3ceeffbcd80f3207a6236c8043d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. Daniel Aletaha
2. J. Smolen

Citations in the corpus

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013, background): “Until then, we hope that the current recommendations will fi nd their way into clinical practice either directly or through national societies that may wish to use them as a framework for development of local guidance documents.”
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Combination therapy of sarilumab andMTX is currently evaluated in a Phase II/III randomized trial in patients with RA, and positive results have been reported (NCT01061736).”